EBE Board Members 2016-2018

  • Eduardo Bravo

    EBE President
    TiGenix, Chief Executive Officer
  • Andrea Chiesi

    EBE Vice-President
    Chiesi Farmaceutici, VP Holostem Advanced Therapies, Director R&D Project Portfolio Management
  • Didier Malherbe

    EBE Treasurer
    UCB, Vice President & Head of Public Affairs UCB and General Manager UCB Belgium
  • Roberto Gradnik

    Ixaltis, Chief Executive Officer
  • Eugenio Aringhieri

    Dompé, Chief Executive Officer
  • Christophe Jean

    Ipsen, Executive Vice President, Corporate Strategy, Business Development, Alliances and M&A
  • Jacky Vonderscher

    Enyo Pharma, Chief Executive Officer & President - joined the EBE Board in September 2017
  • Ahmed Bouzidi

    Vaxeal, Chief Executive Officer
  • Jochen Maas

    Sanofi Aventis Germany, General Manager R&D
  • Herb Riband

    Amgen, Vice President Value, Access & Policy International
  • François Martelet

    NetScientific, CEO
  • Michele Antonelli

    Stallergenes SAS, President Stallergenes SAS and Executive Vice President, Head of Europe and International, Stallergenes-Greer
  • Nicola Beaucamp

    Roche Diagnostics GmbH, Head of Process Research Large Molecule Research, Pharma Research and Early Development

Leadership of EBE working structures

Advanced Therapies (joint Working Group with EFPIA)

Chair: Maria Pascual, TiGenix
Vice-chair: Esther Choi, Bristol-Myers Squibb

Allergen Immunotherapy Task Force

Biomanufacturing Working Group

Chair: Markus Goese, Roche
Vice-chair: Ronald Imhoff, J&J

Biotherapeutics Working Group

Chair: Stephanie Lane, MSD
Vice-chair: Fabio Bisordi, Roche

Cancer Control Task Force

Innovation and Funding Models Working Group

Chair: Roberto Gradnik, Ixaltis
Vice-chair: TBD

Personalised Medicine (joint Working Group with EFPIA)

Chair: Christine Mayer-Nicolai, Merck
Vice-chair: Eelko den Breejen, Roche

Public Affairs Network

Chair: Nathalie Stieger, Roche
Vice-chair: Mazen Elzaabi, LFB Biotechnologies

Regulatory & Technical Affairs Network

Chair: To be appointed
Vice-chair: Emma Dufour, AbbVie